Gloria Mak Ring
Counsel
Boston
gloria.ring@lw.com
+1.617.880.4538
PRACTICES
- Mergers & Acquisitions
- Private Equity
INDUSTRIES
EDUCATION
- JD, University of Virginia School of Law, 2013
- BA, University of Massachusetts, 2008
cum laude
LANGUAGES SPOKEN
- English
PROFILE
Gloria Ring advises clients on all aspects of mergers and acquisitions and financing transactions, particularly involving biotechnology, pharmaceutical, and medical device companies in the life sciences industry.
Gloria leverages her business-focused mindset and a sophisticated understanding of the markets to help strategic buyers and sellers, private equity firms, and their portfolio companies navigate:
- Acquisitions (including cross-border and add-on acquisitions), dispositions, recapitalizations, joint ventures, and auction processes
- Minority investments and financings
- Reorganizations, asset and business division carve-outs, and corporate restructurings
She draws on experience as an in-house lawyer at a public asset management company to bring a well-rounded perspective to each transaction and is able to distill complex deal terms for clients, allowing them to achieve their business goals.
A recognized leader at the firm, Gloria serves on the Recruiting Committee, for which she regularly speaks at diversity recruiting events. She has also served on the Pro Bono Committee, in addition to spearheading the Asian and Middle Eastern Lawyers Group in Boston. Gloria is a member of the Women’s Bar Association of Massachusetts and the Asian American Lawyers Association of Massachusetts.
Gloria maintains an active pro bono practice, focused on election protection work with the Lawyers Committee for Civil Rights and immigration representations through Project Citizenship.
EXPERIENCE
Gloria’s recent experience includes representing:
- Aiolos, a clinical-stage biopharmaceutical company, in its sale to GSK for US$1 billion in upfront consideration and an additional US$400 million in contingent milestone payments
- Jnana Therapeutics, a clinical-stage biotechnology company, in its sale to Otsuka Pharmaceutical for up to US$1.1 billion
- Endotronix, a medical technology company, in its option agreement with, and subsequent acquisition by, Edwards Lifesciences
- Seres Therapeutics (Nasdaq: MCRB), a biotherapeutics company, in its sale of its VOWST business to Nestlé Health Science
- InvetX, a biotechnology company focused on animal health, in its sale to Dechra Pharmaceuticals
- Invaio Sciences, a biotechnology company focused on agriculture, in its acquisition of Peptyde Bio
- Rhythm Therapeutics (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company, in its acquisition of Xinvento B.V.
- Standard Bariatrics, a medical device company, in its sale to Teleflex Incorporated
- TetraGenetics, a biotechnology company, in its sale to AbCellera